CN111328280A - 制备和使用内昔芬的方法 - Google Patents

制备和使用内昔芬的方法 Download PDF

Info

Publication number
CN111328280A
CN111328280A CN201880072905.6A CN201880072905A CN111328280A CN 111328280 A CN111328280 A CN 111328280A CN 201880072905 A CN201880072905 A CN 201880072905A CN 111328280 A CN111328280 A CN 111328280A
Authority
CN
China
Prior art keywords
composition
endoxifen
formula
endoxifene
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880072905.6A
Other languages
English (en)
Chinese (zh)
Inventor
史蒂文·C·夸伊
孙耀临
王龙虎
吴昌容
黄全德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Atosa Therapeutics
Original Assignee
Atosa Therapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=65635248&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN111328280(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Atosa Therapeutics filed Critical Atosa Therapeutics
Priority to CN202310795504.6A priority Critical patent/CN116832020A/zh
Publication of CN111328280A publication Critical patent/CN111328280A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C217/06—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted
    • C07C217/14—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring
    • C07C217/18—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C213/00—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C213/02—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton by reactions involving the formation of amino groups from compounds containing hydroxy groups or etherified or esterified hydroxy groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C213/00—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C213/08—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton by reactions not involving the formation of amino groups, hydroxy groups or etherified or esterified hydroxy groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C213/00—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C213/10—Separation; Purification; Stabilisation; Use of additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/09—Geometrical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Catalysts (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Dental Preparations (AREA)
  • Primary Cells (AREA)
  • Paper (AREA)
CN201880072905.6A 2017-09-11 2018-09-10 制备和使用内昔芬的方法 Pending CN111328280A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202310795504.6A CN116832020A (zh) 2017-09-11 2018-09-10 制备和使用内昔芬的方法

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201762556884P 2017-09-11 2017-09-11
US201762556799P 2017-09-11 2017-09-11
US62/556,799 2017-09-11
US62/556,884 2017-09-11
US201862624787P 2018-01-31 2018-01-31
US62/624,787 2018-01-31
US201862693885P 2018-07-03 2018-07-03
US62/693,885 2018-07-03
PCT/US2018/050272 WO2019051416A1 (en) 2017-09-11 2018-09-10 METHODS FOR THE MANUFACTURE AND USE OF ENDOXIFEN

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202310795504.6A Division CN116832020A (zh) 2017-09-11 2018-09-10 制备和使用内昔芬的方法

Publications (1)

Publication Number Publication Date
CN111328280A true CN111328280A (zh) 2020-06-23

Family

ID=65635248

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201880072905.6A Pending CN111328280A (zh) 2017-09-11 2018-09-10 制备和使用内昔芬的方法
CN202310795504.6A Pending CN116832020A (zh) 2017-09-11 2018-09-10 制备和使用内昔芬的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202310795504.6A Pending CN116832020A (zh) 2017-09-11 2018-09-10 制备和使用内昔芬的方法

Country Status (12)

Country Link
US (12) US11261151B2 (enExample)
EP (1) EP3681491A4 (enExample)
JP (3) JP7766316B2 (enExample)
KR (3) KR20260048646A (enExample)
CN (2) CN111328280A (enExample)
AU (3) AU2018329202B2 (enExample)
CA (1) CA3073836A1 (enExample)
IL (3) IL272924B2 (enExample)
MX (1) MX2020002649A (enExample)
SG (1) SG11202002105WA (enExample)
TW (2) TWI878810B (enExample)
WO (1) WO2019051416A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113975279A (zh) * 2021-10-13 2022-01-28 复旦大学附属肿瘤医院 维拉佐酮及其衍生物在制备抗肿瘤药物中的应用

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3681491A4 (en) 2017-09-11 2021-06-30 Atossa Therapeutics, Inc. PROCESS FOR MANUFACTURING AND USE OF ENDOXIFES
WO2021003433A1 (en) * 2019-07-03 2021-01-07 Atossa Therapeutics, Inc. Sustained release compositions of endoxifen
CN110564962B (zh) * 2019-10-14 2020-12-22 中南大学 一种黑白钨混合矿的冶炼方法
IL314075A (en) * 2022-01-12 2024-09-01 Atossa Therapeutics Inc Compositions of (Z)-endoxifen and methods for their enrichment
EP4514327A1 (en) * 2022-04-26 2025-03-05 Atossa Therapeutics, Inc. High dose endoxifen formulations and methods of use
AU2024294879A1 (en) * 2023-07-19 2026-01-22 Atossa Therapeutics, Inc. Endoxifen compositions and methods of use thereof and synthesis thereof
AU2024409147A1 (en) 2023-12-18 2026-06-25 Atossa Therapeutics, Inc. Oral formulations of (z)-endoxifen and methods of use thereof
AU2025207748A1 (en) 2024-01-08 2026-07-02 Atossa Therapeutics, Inc. Endoxifen for treatment of rare cancers
WO2025207636A1 (en) 2024-03-25 2025-10-02 Atossa Therapeutics, Inc. Endoxifen for treating duchenne muscular dystrophy

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101891635A (zh) * 2009-05-21 2010-11-24 扬子江药业集团有限公司 枸橼酸他莫昔芬的晶型及晶型a的制备方法
CN102448467A (zh) * 2009-05-27 2012-05-09 利西拉公司 治疗局部脂肪组织的给药方法和制剂
WO2014141292A2 (en) * 2013-03-04 2014-09-18 Intas Pharmaceuticals Limited Endoxifen citrate polymorph and process for preparing the same
CN105579044A (zh) * 2013-05-31 2016-05-11 德玛医药 双脱水半乳糖醇及其类似物与衍生物用于治疗复发性恶性神经胶瘤或进行性继发脑瘤的用途
WO2017070651A1 (en) * 2015-10-22 2017-04-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Process for preparing (z)-endoxifen of high purity
WO2017080770A1 (de) * 2015-11-10 2017-05-18 Robert Bosch Gesellschaft Für Medizinische Forschung Mbh Synthese von (z)-endoxifenhydrochlorid

Family Cites Families (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT951631B (it) 1971-03-18 1973-07-10 Richardson Merrell Spa Composti utili per la separazione di isomeri ottici geometrici e strutturali e relativo procedimen to di sintesi
DE3561012D1 (en) 1984-06-12 1987-12-23 Nat Res Dev Preparation of tamoxifen
GB8604528D0 (en) 1986-02-24 1986-04-03 Ici Plc Therapeutic agents
US6881548B2 (en) 1997-05-23 2005-04-19 A&G Pharmaceutical, Inc. Methods and kits for diagnosing tumorigenicity and determining resistance to the antineoplastic effects of antiestrogen therapy
US6638727B1 (en) 1999-01-26 2003-10-28 Cytyc Health Corporation Methods for identifying treating or monitoring asymptomatic patients for risk reduction or therapeutic treatment of breast cancer
US6398765B1 (en) 1999-03-01 2002-06-04 Pro Duct Health, Inc. Apparatus, methods and kits for simultaneous delivery of a substance to multiple breast milk ducts
US6245352B1 (en) 1999-04-27 2001-06-12 Eli Lilly And Company Pharmaceutical formulation
WO2001001962A1 (en) 1999-07-05 2001-01-11 Idea Ag. A method for the improvement of transport across adaptable semi-permeable barriers
GB0000313D0 (en) 2000-01-10 2000-03-01 Astrazeneca Uk Ltd Formulation
GB0008172D0 (en) 2000-04-05 2000-05-24 Astrazeneca Ab Therapy
US6416981B1 (en) 2000-05-23 2002-07-09 Nec Partnership Production of gluconate salts
WO2003039530A1 (en) 2001-11-07 2003-05-15 Synthon B.V. Tamsulosin tablets
EP2050443B1 (en) 2002-12-18 2017-05-24 Besins Healthcare Luxembourg SARL Reduction of breast density with 4-hydroxy tamoxifen
EP1572178B1 (en) 2002-12-18 2006-05-03 Laboratoires Besins International Treatment of mastalgia with 4-hydroxy tamoxifen
CA2519980C (en) 2003-04-01 2012-04-10 Laboratoires Besins International Prevention and treatment of breast cancer with 4-hydroxy tamoxifen
NZ544851A (en) 2003-06-23 2008-03-28 Macrochem Corp A vanishing cream base composition suitable for topical administration of an active agent to an animal or plant
US7531578B2 (en) 2003-09-18 2009-05-12 City Of Hope Compounds and methods for treating breast cancer and other diseases
US7968532B2 (en) 2003-12-15 2011-06-28 Besins Healthcare Luxembourg Treatment of gynecomastia with 4-hydroxy tamoxifen
ATE548375T1 (de) 2004-01-16 2012-03-15 Cedarburg Pharmaceuticals Inc Exemestan und zwischenprodukte davon und verfahren zu dessen herstellung
US8436029B2 (en) 2004-03-19 2013-05-07 Transform Pharmaceuticals, Inc. Pharmaceutical forms, and methods of making and using the same
US7507769B2 (en) 2004-03-22 2009-03-24 Laboratoires Besins International Treatment and prevention of benign breast disease with 4-hydroxy tamoxifen
CA2603857A1 (en) 2005-03-31 2006-11-16 Mytogen, Inc. Treatment for heart disease
US20060280795A1 (en) 2005-06-08 2006-12-14 Dexcel Pharma Technologies, Ltd. Specific time-delayed burst profile delivery system
KR100917698B1 (ko) 2005-07-06 2009-09-21 시코르, 인크. 레트로졸의 제조를 위한 개선된 방법
CA2617934A1 (en) 2005-08-05 2007-02-15 Nuvo Research Inc. Transdermal drug delivery formulation
US8034824B2 (en) 2005-10-12 2011-10-11 Kowa Co., Ltd. Iontophoretic preparation for treatment of breast cancer and/or mastitis
WO2007067773A2 (en) 2005-12-09 2007-06-14 Mayo Foundation For Medical Education And Research Assessing outcomes for breast cancer patients by determining cyp2d6 genotype
ES2540561T3 (es) 2005-12-20 2015-07-10 Incyte Corporation N-hidroxiamidinoheterociclos como moduladores de indolamina 2,3-dioxigenasa
US9308181B2 (en) 2006-03-06 2016-04-12 Nuvo Research Inc. Topical formulations, systems and methods
US8058302B2 (en) 2006-06-05 2011-11-15 Cadila Healthcare Limited Process for preparing pure anastrozole
US20100098735A1 (en) 2006-10-05 2010-04-22 Rajesh Jain Injectable depot compositions and its process of preparation
US20120164075A1 (en) * 2006-11-21 2012-06-28 Jina Pharmaceuticals, Inc. Endoxifen methods and compositions in the treatment of mammalian diseases
US20090291134A1 (en) 2006-11-21 2009-11-26 Jina Pharmaceuticals, Inc. Endoxifen methods and compositions in the treatment of psychiatric and neurodegenerative diseases
PT2101731T (pt) 2006-11-21 2018-04-18 Jina Pharmaceuticals Inc Endoxifeno para utilização no tratamento de cancro
WO2008066783A2 (en) 2006-11-27 2008-06-05 Ariad Pharmaceuticals, Inc. Therapeutic materials and methods
WO2008067991A2 (en) 2006-12-08 2008-06-12 Antares Pharma Ipl Ag Skin-friendly drug complexes for transdermal administration
WO2008113177A1 (en) 2007-03-20 2008-09-25 Centre De Recherche Sur Les Biotechnologies Marines Compositions comprising polyunsaturated fatty acid monoglycerides or derivatives thereof and uses thereof
US8454945B2 (en) 2007-03-22 2013-06-04 Berg Pharma Llc Topical formulations having enhanced bioavailability
US20090068190A1 (en) 2007-08-29 2009-03-12 Drugtech Corporation Anti-proliferative combinations
AR068409A1 (es) 2007-09-14 2009-11-18 Drugtech Corp Composiciones farmaceuticas, transdermicas sin alcohol
EP2212301B1 (en) 2007-11-28 2012-02-29 Fresenius Kabi Oncology Limited An improved process for preparation of letrozole and its intermediates
WO2009120999A2 (en) 2008-03-28 2009-10-01 Olema Pharmaceuticals, Inc. Use of an endoxifen prodrug for treatment of breast cancer
WO2009129352A2 (en) 2008-04-15 2009-10-22 Windy Hill Medical Device and method for accessing and treating ducts of mammary glands
US8063249B1 (en) 2008-04-25 2011-11-22 Olema Pharmaceuticals, Inc. Substituted triphenyl butenes
CA3012229C (en) 2008-07-08 2020-11-10 Incyte Holdings Corporation 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase
WO2010009335A1 (en) 2008-07-17 2010-01-21 Micell Technologies, Inc. Drug delivery medical device
WO2010043404A1 (en) 2008-10-15 2010-04-22 Synthon B.V. Processes and intermediates for the production of fulvestrant
US20100098659A1 (en) 2008-10-22 2010-04-22 Revalesio Corporation Compositions and methods for treating matrix metalloproteinase 9 (mmp9)-mediated conditions
ES2624557T3 (es) 2008-12-11 2017-07-14 Besins Healthcare Luxembourg Sarl Composiciones farmacéuticas transdérmicas que comprenden un SERM
US20100317635A1 (en) 2009-06-16 2010-12-16 Endorecherche, Inc. Treatment of hot flushes, vasomotor symptoms, and night sweats with sex steroid precursors in combination with selective estrogen receptor modulators
WO2011031561A2 (en) 2009-08-27 2011-03-17 Ensisheim Partners Llc Nucleic acid molecules and uses thereof
US8637569B2 (en) 2009-10-22 2014-01-28 Api Genesis, Llc Methods of increasing solubility of poorly soluble compounds and methods of making and using formulations of such compounds
WO2011072244A1 (en) 2009-12-10 2011-06-16 Mount Sinai School Of Medicine Of New York University Method of treatment of breast cancer with tamoxifen
EP2425833A1 (de) 2010-09-03 2012-03-07 Fresenius Kabi Deutschland GmbH Die intravenöse Applikation von Fischöl/DHA +EPA vor bzw. mit Beginn der Chemotherapie
KR101308258B1 (ko) 2010-10-15 2013-09-13 씨제이제일제당 (주) 엔독시펜의 신규한 제조 방법
EP2468264A1 (en) 2010-12-27 2012-06-27 Laboratorios Liconsa, S.A. Oral pharmaceutical tablet for controled release of mesalazine and process for obtaining it
US9200045B2 (en) 2011-03-11 2015-12-01 President And Fellows Of Harvard College Small molecule-dependent inteins and uses thereof
EP2508174A1 (en) 2011-04-06 2012-10-10 Ljiljana Sovic Brkicic Pharmaceutical composition
WO2012162492A1 (en) 2011-05-24 2012-11-29 Teva Pharmaceutical Industries Ltd. Compressed core comprising organic acids for a pharmaceutical composition
WO2013033430A1 (en) 2011-09-02 2013-03-07 Wake Forest School Of Medicine Targeted delivery and prodrug designs for platinum-acridine anti-cancer compounds and methods thereof
FR2980972B1 (fr) 2011-10-05 2014-02-28 Commissariat Energie Atomique Formulations pour le diagnostic et le traitement de cancers hormonodependants et de cancers des organes de synthese d'hormones steroidiennes.
WO2013134230A1 (en) 2012-03-05 2013-09-12 Xavier University Boron-based 4-hydroxytamoxifen and endoxifen prodrugs as treatment for breast cancer
US9220680B2 (en) 2012-07-13 2015-12-29 South Dakota State University Compositions and methods for localized drug delivery through mammary papillae
US20150321983A1 (en) 2012-10-19 2015-11-12 Fermion Oy A process for the preparation of ospemifene
EP2922847A1 (en) 2012-11-20 2015-09-30 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of indoleamine 2,3-dioxygenase
IL298125A (en) 2013-02-26 2023-01-01 Memorial Sloan Kettering Cancer Center Preparations and methods for immunotherapy
CN105492011A (zh) 2013-04-08 2016-04-13 丹尼斯·M·布朗 不理想给药化学化合物的治疗增效
EP3057985A4 (en) 2013-10-18 2017-05-31 The Regents Of The University Of Michigan Systems and methods for determining a treatment course of action
HUP1300646A2 (en) 2013-11-12 2015-05-28 Druggability Technologies Ip Holdco Jersey Ltd Complexes of fulvestrant and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them
EP3092027A4 (en) 2014-01-10 2017-09-06 Atossa Genetics Inc. Transpapillary methods and compositions for diagnosing and treating breast conditions
US9744177B2 (en) 2014-03-10 2017-08-29 Endorecherche, Inc. Treatment of male androgen deficiency symptoms or diseases with sex steroid precursor combined with SERM
CA2942301A1 (en) 2014-03-11 2015-09-17 Repros Therapeutics Inc. Clomiphene synthesis using a single solvent
EP3152579A4 (en) 2014-06-04 2018-01-17 Atossa Genetics Inc. Molecular mammography
CN104230723B (zh) 2014-08-21 2016-08-24 凯莱英医药集团（天津）股份有限公司 托瑞米芬的合成方法
EP3283061A4 (en) 2015-04-14 2019-04-17 Atossa Genetics Inc. COMPOSITIONS AND METHODS FOR THE TREATMENT OF BREAST DISEASES AND ORGANISM-RELATED ILLNESSES
WO2016187122A1 (en) 2015-05-15 2016-11-24 University Of Iowa Research Foundation Methods for treating tumors in situ including intratumor injection of cytotoxic particles and immune checkpoint blockade therapy
CA2992282A1 (en) 2015-07-14 2017-01-19 Atossa Genetics Inc. Transpapillary methods and compositions for treating breast disorders
US20170304232A1 (en) 2016-04-20 2017-10-26 Northwestern University Endoxifen For Local Transdermal Therapy To The Breast
CN111212635A (zh) 2017-09-11 2020-05-29 阿托莎医疗公司 局部用组合物
TW201919594A (zh) 2017-09-11 2019-06-01 美商艾陶莎基因有限公司 局部用組合物及治療方法
EP3681491A4 (en) 2017-09-11 2021-06-30 Atossa Therapeutics, Inc. PROCESS FOR MANUFACTURING AND USE OF ENDOXIFES

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101891635A (zh) * 2009-05-21 2010-11-24 扬子江药业集团有限公司 枸橼酸他莫昔芬的晶型及晶型a的制备方法
CN102448467A (zh) * 2009-05-27 2012-05-09 利西拉公司 治疗局部脂肪组织的给药方法和制剂
WO2014141292A2 (en) * 2013-03-04 2014-09-18 Intas Pharmaceuticals Limited Endoxifen citrate polymorph and process for preparing the same
CN105579044A (zh) * 2013-05-31 2016-05-11 德玛医药 双脱水半乳糖醇及其类似物与衍生物用于治疗复发性恶性神经胶瘤或进行性继发脑瘤的用途
WO2017070651A1 (en) * 2015-10-22 2017-04-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Process for preparing (z)-endoxifen of high purity
WO2017080770A1 (de) * 2015-11-10 2017-05-18 Robert Bosch Gesellschaft Für Medizinische Forschung Mbh Synthese von (z)-endoxifenhydrochlorid

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113975279A (zh) * 2021-10-13 2022-01-28 复旦大学附属肿瘤医院 维拉佐酮及其衍生物在制备抗肿瘤药物中的应用

Also Published As

Publication number Publication date
IL304863B2 (en) 2025-08-01
SG11202002105WA (en) 2020-04-29
IL304863B1 (en) 2025-04-01
US20250223256A1 (en) 2025-07-10
US20240425443A1 (en) 2024-12-26
IL304863A (en) 2023-10-01
JP7766316B2 (ja) 2025-11-10
MX2020002649A (es) 2020-09-25
US11572334B2 (en) 2023-02-07
AU2024278243A1 (en) 2025-01-02
AU2018329202B2 (en) 2022-10-27
JP7901563B2 (ja) 2026-08-06
WO2019051416A1 (en) 2019-03-14
IL319158A (en) 2025-04-01
US11261151B2 (en) 2022-03-01
EP3681491A1 (en) 2020-07-22
AU2023200013A1 (en) 2023-02-09
TW202428251A (zh) 2024-07-16
JP2020533283A (ja) 2020-11-19
TWI878810B (zh) 2025-04-01
US20250282710A1 (en) 2025-09-11
US20260200829A1 (en) 2026-07-16
AU2023200013B2 (en) 2024-09-12
US20230183166A1 (en) 2023-06-15
KR20260048646A (ko) 2026-04-10
CA3073836A1 (en) 2019-03-14
US20220242816A1 (en) 2022-08-04
AU2018329202A1 (en) 2020-03-19
US20240327333A1 (en) 2024-10-03
KR20200052349A (ko) 2020-05-14
US20260200828A1 (en) 2026-07-16
US20260200827A1 (en) 2026-07-16
IL272924B1 (en) 2023-09-01
JP2023126540A (ja) 2023-09-07
EP3681491A4 (en) 2021-06-30
JP2025061858A (ja) 2025-04-11
IL272924A (en) 2020-04-30
TW201919596A (zh) 2019-06-01
US11680036B1 (en) 2023-06-20
IL272924B2 (en) 2024-01-01
US12479790B2 (en) 2025-11-25
US12281056B2 (en) 2025-04-22
US20260028308A1 (en) 2026-01-29
CN116832020A (zh) 2023-10-03
KR20240155974A (ko) 2024-10-29
US12275684B2 (en) 2025-04-15
TWI793165B (zh) 2023-02-21
US20230365490A1 (en) 2023-11-16
US12071391B2 (en) 2024-08-27
US20200207704A1 (en) 2020-07-02

Similar Documents

Publication Publication Date Title
US12281056B2 (en) Methods for making and using endoxifen
JP2023126540A5 (enExample)
TW202340135A (zh) （ｚ）—因多昔芬之組合物及其富集方法
CN121568688A (zh) 因多昔芬组合物及其使用方法及其合成
HK40093298A (en) Methods for making and using endoxifen
HK40031003A (en) Methods for making and using endoxifen
HK40109762A (en) Compositions of (z)-endoxifen and methods of enrichment thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40031003

Country of ref document: HK

WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20200623

WD01 Invention patent application deemed withdrawn after publication